ArticleCancer reports (Hoboken, N.J.)2026
DKK1 Promotes Cisplatin Resistance in Oral Squamous Cell Carcinoma via SLC3A2-Dependent Ferroptosis Suppression.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundOral squamous cell carcinoma (OSCC) is a prevalent malignancy associated with poor outcomes, largely attributable to cisplatin resistance-the standard chemotherapeutic agent.
aimsWhile ferroptosis has been proposed as a promising therapeutic target, how it is regulated in OSCC remains largely unclear. METHODS AND
resultsTo determine DKK1 expression levels and their prognostic implication, the TCGA-HNSC cohort and OSCC patient samples were examined. The impact of DKK1 silencing and/or cisplatin treatment on cell proliferation and ferroptosis-related markers, including reactive oxygen species (ROS), malondialdehyde (MDA), and glutathione (GSH) levels, was investigated in vitro. Additionally, the efficacy of DKK1 inhibition was evaluated in xenograft models. The findings revealed that DKK1 expression was markedly elevated in the TCGA-HNSC cohort and was further validated in OSCC tissues. High DKK1 expression was associated with worse survival and contributed to cisplatin resistance, while DKK1 silencing sensitized cells to ferroptosis and enhanced cisplatin cytotoxicity. Mechanistically, our data support a regulatory model in which DKK1 maintains SLC3A2 expression through modulation of the β-catenin/STAT3 axis, thereby contributing to ferroptosis suppression and cisplatin resistance. In vivo, DKK1 inhibition improved cisplatin efficacy, at least in part, by promoting SLC3A2-associated ferroptosis.
conclusionThese findings support DKK1 as a potential regulator of ferroptosis and cisplatin resistance in OSCC. Targeting the DKK1/SLC3A2 axis to restore ferroptotic sensitivity may represent a promising strategy to overcome chemoresistance.
Indexed as
Identifiers
42850688What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.